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IMPORTANCE Psychotic experiences, such as hallucinations and delusions, are reported by
approximately 5% to 10% of the general population, although only a small proportion
develop psychotic disorders such as schizophrenia. Studying the genetic causes of psychotic
experiences in the general population, and its association with the genetic causes of other
disorders, may increase the understanding of their pathologic significance.
OBJECTIVES To determine whether genetic liability to psychotic experiences is shared with
schizophrenia and/or other neuropsychiatric disorders and traits and to identify genetic loci
associated with psychotic experiences.
DESIGN, SETTING AND PARTICIPANTS Analyses of genetic correlation, polygenic risk scores,
and copy number variation were performed using data from participants in the UK Biobank
from April 1, 2018, to March 20, 2019, to assess whether genetic liability to psychotic
experiences is shared with schizophrenia and/or other neuropsychiatric disorders and traits.
Genome-wide association studies of psychotic experience phenotypes were conducted to
identify novel genetic loci. Participants in the final analyses after exclusions included 6123
individuals reporting any psychotic experience, 2143 individuals reporting distressing
psychotic experiences, and 3337 individuals reporting multiple occurrences of psychotic
experiences. A total of 121 843 individuals who did not report a psychotic experience formed
the comparator group. Individuals with a psychotic disorder were excluded from all analyses.
MAIN OUTCOMES ANDMEASURES Genetic associations with psychotic experience
phenotypes.
RESULTS The study included a total of 127 966 participants (56.0%women and 44.0%men;
mean [SD] age, 64.0 [7.6] years). Psychotic experiences were genetically correlated with
major depressive disorder, schizophrenia, autism spectrum disorder, and attention-deficit/
hyperactivity disorder. Analyses of polygenic risk scores identified associations between
psychotic experiences and genetic liability for major depressive disorder, schizophrenia,
bipolar disorder, autism spectrum disorder, and attention-deficit/hyperactivity disorder.
Individuals reporting psychotic experiences had an increased burden of copy number
variations previously associated with schizophrenia (odds ratio [OR], 2.04; 95% CI, 1.39-2.98;
P = 2.49 × 10−4) and neurodevelopmental disorders more widely (OR, 1.75; 95% CI,
1.24-2.48; P = 1.41 × 10−3). Genome-wide association studies identified 4 significantly
associated loci, including a locus in Ankyrin-3 (ANK3 [GenBank NM_020987]) (OR, 1.16; 95%
CI, 1.10-1.23; P = 3.06 × 10−8) with any psychotic experience, and a locus in cannabinoid
receptor 2 gene (CNR2 [GenBank NM_001841]) (OR, 0.66; 95% CI, 0.56-0.78;
P = 3.78 × 10−8) with distressing psychotic experiences. The genome-wide association study
of any psychotic experience had a low single-nucleotide polymorphism–based heritability
estimate (h2 = 1.71%; 95% CI, 1.02%-2.40%).
CONCLUSIONS AND RELEVANCE A large genetic association study of psychotic experiences
from the population-based UK Biobank sample found support for a shared genetic liability
between psychotic experiences and schizophrenia, major depressive disorder, bipolar
disorder, and neurodevelopmental disorders.
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P sychotic experiences, such as hallucinations anddelu-sions, are features of psychiatric disorders (eg, schizo-phrenia), but they are also reported by approximately
5% to 10% of the general population.1,2 Psychotic experi-
encesareconsidered tobesymptomsofpsychiatric illnessonly
if they co-occur with other features of that disorder, includ-
ing someaspectofpsychosocial impairment. It is currentlyun-
clear whether psychotic experiences in the general popula-
tion are: (1) on a spectrum that, at the extreme, is associated
specificallywith schizophrenia, (2) largely unassociatedwith
the psychotic symptoms experienced in schizophrenia and
other major mental disorders, or (3) associated with liability
to major mental disorders more generally.
Twin studies and genome-wide association studies
(GWASs) have provided evidence that psychotic experiences
are heritable (30%-50% from twin studies,3-5 and 3%-17% for
single-nucleotide polymorphism [SNP]–heritability
estimates6,7), indicating that common genetic variants play a
role in their liability. There have been 3 GWASs of psychotic
experiences to date in adolescent samples7-9 and no reported
genome-wide significant findings. Although therewas an ini-
tial assumption that psychotic experiences in adolescence
would specifically increase the risk for schizophrenia in later
life, epidemiologic evidence suggests a nonspecific in-
creased risk for broader psychopathologic characteristics.10
However, to date, no study has found strong evidence for an
associationbetweengenetic liabilities for schizophreniaor any
other mental disorder and psychotic experiences.7,8,11-13
Althoughmany individualswith a lifetimehistory of psy-
chotic experiences have their first experience in adoles-
cence, nearly one-quarter of first-onset psychotic experi-
ences occur after 40 years of age.14 Our aimswere to use data
from the UK Biobank to identify genetic loci associated with
psychotic experiences reported by adults in a population-
based study, and todeterminewhether genetic liability topsy-
chotic experiences is sharedwith schizophrenia and/or other
neuropsychiatric disorders and traits.
Methods
Sample
Study individualswere from theUKBiobank, a large prospec-
tivepopulation-basedcohort studyof approximately 500000
individuals between 40 and 69 years of age who were re-
cruited from across the UK between 2006 and 2010.15 The
NorthWestMulti-CentreEthicsCommitteegrantedethical ap-
proval toUKBiobank andall participants providedwritten in-
formed consent. This study was conducted under UK Bio-
bank project numbers 13310 and 14421.
Psychotic Experiences Phenotypes
AMental Health Questionnaire (MHQ) was sent to all partici-
pantswhoprovidedanemail address fromJuly 13,2016, to July
27, 2017, andwas completed by 157 387 individuals (46.4% of
thoseemailed; 31.4%of the totalUKBiobank sample). Forpsy-
chotic experiences,participantswereaskedaboutpreviousex-
perienceof visual hallucinations, auditoryhallucinations, de-
lusions of reference, delusions of persecution, as well as how
often these experiences occurred and how distressing they
found them (eAppendix in the Supplement). Individualswith
adiagnosisof schizophrenia,bipolardisorder,oranyotherpsy-
choticdisorderwere identifiedusingall available sources (hos-
pital records, death records, or self-report at the interview or
from the MHQ) and were excluded from all analyses (full de-
tails in eMethods 1 in the Supplement).
We selected 3 primary phenotypes for GWASs (eFigure 1
in the Supplement): (1) any psychotic experience defined as a
positive response to anyof the4 symptomquestions (UKBio-
bank field IDs: 20463, 20468, 20471, and 20474); (2) a dis-
tressingpsychotic experience, defined as anypsychotic expe-
rience that was rated as “a bit,” “quite,” or “very” distressing
(UKBiobank field ID: 20462); and (3)multiple occurrences of
psychotic experiences, defined as any psychotic experience
that occurred onmore than 1 occasion (UK Biobank field IDs:
20465, 20470, 20473, and20476). As a comparator group,we
included individuals who provided a negative response to all
4 psychotic experience symptom questions. In addition, we
investigated each individual psychotic experience symptom
for association with polygenic risk scores (PRSs).
Genetic Data
Genetic data for the study participants were provided by UK
Biobankandthe imputationandquality controlproceduresare
fullydescribedelsewhere.16Thedata releasecontained488377
participants assayed on either the UK Biobank Axiom or the
UK BiLEVE Axiom purpose-built arrays at the Affymetrix Re-
search Services Laboratory. Standard quality control proce-
dures were applied prior to imputation using Haplotype Ref-
erenceConsortium17 andUK10Khaplotype reference18panels.
We applied additional quality control filters to select high-
quality SNPs,19 minor allele frequency greater than 0.01, im-
putation score greater than 0.8, missingness less than 0.05,
Hardy-Weinberg equilibriumPvalue greater than 1 × 10−6 and
removed SNPs imputed by the UK10K haplotype reference18
data set in accordance with guidance from the UK Biobank
(http://www.ukbiobank.ac.uk/2017/07/important-note-about-
imputed-genetics-data/). Onemember fromeach related pair
with akinship coefficient greater than0.15was excluded from
Key Points
Question Is the genetic liability to psychotic experiences shared
with schizophrenia and/or other neuropsychiatric disorders and
traits?
Findings In this cohort study, genetic correlation, polygenic risk
score, and copy number variation analyses indicated a shared
genetic liability between psychotic experiences andmajor
depressive disorder, schizophrenia, bipolar disorder, and
neurodevelopmental disorders. Genome-wide association studies
identified 4 genetic loci associated with psychotic experiences
including loci in ANK3 and CNR2.
Meaning Findings suggest that the genetic liability of psychotic
experiences is shared with several psychiatric disorders, which
include, but is not specific to, schizophrenia.
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analyses, preferentially retaining individuals who had
experienced a psychotic experience, and were otherwise
removed at random.
Analyses were restricted to individuals with a self-
reportedBritishandIrishethnicity (UKBiobankfield ID:21000)
andprincipal components supplied byUKBiobank16 (UKBio-
bank field ID: 22009) were used to make additional exclu-
sions and control for population structure (described in
eMethods 2 and eFigures 2 and 3 in the Supplement).
GWASAnalysis
To identify genetic risk variants for psychotic experiences, as-
sociation analysiswasperformed in SNPTEST, version2.5.420
using bgen, version 1.2 imputed dosage data.21 More than 7.5
million SNPs were included in each GWAS. An additive logis-
tic regressionmodelwasused includingascovariates thegeno-
typing array, the top 5 principal components (as recom-
mended for most GWAS approaches22), and any additional
principal components from the first 20 that were nominally
associated (P < .05)with theGWASphenotype in a logistic re-
gression. To obtain relatively independent index SNPs, link-
age disequilibrium (LD) clumping was performed in PLINK23
(r2 < 0.1;P < 1 × 10−4;windowsize,<3MB) foreachGWASusing
a reference panel of 1000 randomly selected individualswith
confirmed European ancestry in the UK Biobank. Functional
annotationwasconductedusingFUMA24andLDSC25wasused
to calculate the LD score intercept and heritability on the ob-
served scale using the summary statistics from each psy-
chotic experience GWAS.
Validation Analyses in the Avon Longitudinal Study
of Parents and Children Cohort
Toassess thereproducibilityof thepsychoticexperienceGWAS,
we used the summary statistics from the GWAS of any psy-
chotic experience to target psychotic experiences in theAvon
Longitudinal Study of Parents and Children (ALSPAC)
cohort,26,27whichhavebeenpreviouslydescribed.11,28Thepsy-
chotic experiencePRSwas generated for eachALSPACpartici-
pant using the widely used method29 and logistic regression
was used to test for an association between PRS and psy-
chotic experiences reportedat 12and18yearsof age (eMethods
3 in the Supplement).
Genetic Correlations
LDSC25,30 was used to calculate the genetic correlation be-
tween the GWAS of any psychotic experience and other psy-
chiatric and personality traits. External GWAS data sets (that
didnot includedata fromtheUKBiobankwherepossible)used
to generate the correlations included schizophrenia,31 bipo-
lar disorder,32 major depressive disorder,33 attention-deficit/
hyperactivitydisorder (ADHD),34 autismspectrumdisorder,35
neuroticism,36 and intelligence.37ABonferroni correctionwas
applied to control for multiple testing.
Polygenic Risk Scores
PRSswere generated to investigate additional psychotic expe-
rience phenotypes that were not sufficiently powered for ge-
netic correlationanalyses.Weselected the samesummary sta-
tistics used for genetic correlations to create the risk scores for
UKBiobankparticipantsusingthemethoddescribedbythePsy-
chiatricGenomicsConsortium29 anddetailed ineMethods4 in
theSupplement.TheintelligenceGWASsummarystatisticsused
in this studyspecificallyexcludedparticipants fromtheUKBio-
bank (74214 individuals remaining). None of the other train-
ing sets included the UK Biobank as a contributing sample, al-
thoughwewere not able to test for duplicates at the genotype
level andsocannot ruleduplicatesout.Given thispotential for
sample overlap with the training sets, PRS results should be
treatedwith a degree of caution and are used primarily to sup-
port and extend findings from genetic correlation analysis
(which allows for overlapping samples). The primary analysis
used standardized scores generated from SNPs with a discov-
ery sample P value threshold of P ≤ .05, but associations at 10
otherP value thresholdswere also tested. A logistic regression
model was used to test the association of each PRS with vari-
ous psychotic experience phenotypes, covarying for the first 5
principal components and genotyping array.
Copy Number Variation
Copy number variation (CNV) calling for the UK Biobank has
been described in detail elsewhere38 and is detailed in
eMethods 5 in the Supplement.We compared carrier status of
rareCNVspreviouslyassociatedwithschizophrenia39andneu-
rodevelopmental disorders more widely40 with the 3 pri-
mary psychotic experience phenotypes used for GWASs. As-
sociation analyses were carried out using logistic regression
and included age, sex, and genotyping array as covariates.
Results
A total of 7803 (5.0%; 60.0% women and 40.0%men; mean
[SD]age,62.7 [7.7] years) individuals fromtheUKBiobankwho
completed theMHQ reported at least 1 psychotic experience,
3012 individuals rated the psychotic experience as distress-
ing, and a total of 4388 individuals reported multiple occur-
rences of at least 1 psychotic experience. A total of 147461 in-
dividuals (56.0%womenand44.0%men;mean [SD] age, 64.1
[7.6] years) who reported no psychotic experiences consti-
tuted the comparison group for our association analyses. The
mean (SD) age of the first psychotic experiencewas 31.6 (17.6)
years (eFigure4 in theSupplement),with2341of6654 (35.2%)
first occurring before the age of 20 years or for as long as the
participant could remember, 2137 (32.1%) between the ages of
20 and 39 years, and 2176 (32.7%) between the ages of 40 and
76 years.We excluded 198 individualswho had a diagnosis of
schizophrenia, 818 with bipolar disorder, and 346 with other
psychotic disorders from all genetic analyses (detailed in
eMethods 1 in the Supplement).
Genome-Wide Association Studies
TheGWASofanypsychoticexperience in6123casesand121843
controls (afterquality control; exclusionsdetailed ineMethods
6 in the Supplement) identified 2 variants that were associ-
ated at the genome-wide significance level of P < 5 × 10−8
(Figure 1, Table 1; λGC = 1.05, LD score regression inter-
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cept = 1.00): rs10994278, an intronic variant within An-
kyrin-3 (ANK3 [GenBank NM_020987]) (odds ratio [OR], 1.16;
95% CI, 1.10-1.23; P = 3.06 × 10−8), and intergenic variant
rs549656827 (OR, 0.61; 95% CI, 0.50-0.73; P = 3.30 × 10−8).
A second GWAS restricting the cases to 2143 individuals
with distressing psychotic experiences identified 2 genome-
wide significance variants (Table 1; λGC = 1.03, LD score inter-
cept = 1.01): rs75459873, intronic to cannabinoid receptor 2
(CNR2 [GenBank NM_001841]) (OR, 0.66; 95% CI, 0.56-0.78;
P = 3.78 × 10−8), and intergenic variant rs3849810 (OR, 1.22;
95% CI, 1.13-1.31; P = 4.55 × 10−8).
The third GWAS restricting the cases to 3337 individuals
who reported multiple occurrences of psychotic experiences
did not identify any associated variants at genome-wide sig-
nificance (λGC = 1.03, LD score intercept = 1.00). QQ plots for
each GWAS are displayed in eFigure 5 in the Supplement and
LocusZoom plots for each genome-wide significant locus are
provided in eFigure 6 in the Supplement.
Figure 1. Manhattan Plot for Genome-Wide Association Study Analyses of Any Psychotic Experience,
Distressing Psychotic Experiences, andMultiple Occurrences of Psychotic Experiences
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Single-nucleotide polymorphism–based heritability esti-
mates calculatedbyLDSC25 for theGWASof anypsychotic ex-
perience was h2 = 1.71% (95% CI, 1.02%-2.40%). The other
GWASanalysesdidnot requirements (casen>5000and z score
>441) forheritabilityor genetic correlationanalyseswithLDSC.
None of the associated regions from the GWAS for any psy-
choticexperienceanddistressingpsychoticexperienceshowed
evidence of colocalization42 with schizophrenia,31 bipolar
disorder,32 or major depressive disorder.33
Validation Analyses in ALSPAC
Therewas evidence of an association between the PRS calcu-
latedusing theGWASof anypsychotic experience fromtheUK
Biobanksampleat thePvalue thresholdof≤.5anddefinitepsy-
chotic experiences between 12 and 18 years of age in ALSPAC
(OR, 1.13; 95%CI, 1.02-1.25;R2 = 0.002; P = .02). This finding
was consistent for thresholds above P < .05 and when using
measures fromage 18 years only (eFigure 7 and eTable 1 in the
Supplement).However, thepsychoticexperiencesPRSwasalso
associated with the presence of major depressive disorder at
18yearsof age (OR, 1.19;95%CI, 1.05-1.35;R2 = 0.004;P = .01).
Link Between Association at CNR2 and Cannabis Use
We investigated, but found no evidence for, a mediating or
moderating association of cannabis use with the association
betweendistressingpsychotic experiences and rs75459873 at
the cannabinoid receptor gene CNR2. Cannabis use itself (UK
Biobank field ID: 20453)was significantly associatedwithdis-
tressing psychotic experiences (OR, 1.36; 95% CI, 1.32-1.40;
P = 9.16 × 10−88), but rs75459873wasnot associatedwith can-
nabis use (OR, 0.99; 95% CI, 0.95-1.04; P = .70). Further-
more, theassociationbetweenrs75459873anddistressingpsy-
chotic experiences was unchanged in a model including
cannabis use as a covariate (OR, 0.62; 95%CI, 0.52-0.75) or as
an interaction term (OR, 0.59; 95% CI, 0.48-0.73; P = .31 for
interaction).
Genetic Correlations
Significantgenetic correlations (rg)wereobservedbetweenany
psychotic experienceandmajordepressivedisorder (rg = 0.46;
P = 4.64 × 10−11), autism spectrum disorder (rg = 0.39;
P = 1.68 × 10−4), ADHD (rg = 0.24;P = 4.61 × 10−3), and schizo-
phrenia (rg = 0.21;P = 7.29 × 10−5).Figure 2displays these ge-
netic correlations and eTable 2 in the Supplement details the
full results. The other psychotic experience GWASs did not
meet requirements41 for genetic correlation analysis.
PRS Analysis
We found evidence of a weak association between any psy-
chotic experience and genetic liability, indicated by PRS at a
P < .05threshold forSNPinclusion, forschizophrenia (OR, 1.09;
95% CI, 1.06-1.12; adjusted R2 = 0.001; P = 2.96 × 10−11), ma-
jor depressivedisorder (OR, 1.16; 95%CI, 1.13-1.19;R2 = 0.003;
P = 1.48 × 10−30), bipolar disorder (OR, 1.07; 95% CI, 1.04-
1.10;R2 = 0.001;P = 5.11 × 10−7),ADHD(OR, 1.06;95%CI, 1.03-
1.09;R2 = 0.0005; P = 5.73 × 10−6), and autism spectrumdis-
order (OR, 1.07; 95%CI, 1.04-1.10;R2 = 0.001;P = 1.34 × 10−5).
These associationswere stronger for distressingpsychotic ex-
periences (Figure 3; eTable 2 in the Supplement) and consis-
tent across most P value thresholds (eFigures 8 and 9 in the
Supplement).We also considered individual psychotic symp-
toms and found that PRSs for schizophrenia, bipolar disor-
der,depression, andADHDweremorestronglyassociatedwith
delusions of persecution thanwith the other psychotic symp-
toms (eTable 3 andeFigures 10-12 in the Supplement). The as-
sociationwithpsychoticexperiencephenotypes forbipolardis-
order PRS and major depressive disorder PRS remained
significant in analyses controlling for schizophrenia PRS
(eTable 4 in the Supplement). The associationwithmajor de-
pressive disorder PRS remained significant when individuals
with a diagnosis of depressionwere removed (eTable 5 in the
Supplement). Given the potential for sample overlapwith the
training sets, PRS findings should be treated with a degree of
caution.
Copy Number Variation
Individuals reportingdistressingpsychotic experiences inpar-
ticular had an increased burden of CNVs previously associ-
ated with schizophrenia (OR, 2.04; 95% CI, 1.39-2.98;
P = 2.49 × 10−4) andneurodevelopmental disorders (OR, 1.75;
95% CI, 1.24-2.48; P = 1.41 × 10−3). There was evidence of an
increased burden of these CNVs in individuals reporting any
psychotic experience, but not multiple occurrences of psy-
chotic experiences (Table 2).
Discussion
We conducted the largest genetic-association study of psy-
chotic experiences, to our knowledge, using the population-
basedUKBiobank sample and found evidence of a shared ge-
netic liability between psychotic experiences and several
psychiatric disorders,which included, butwasnot specific to,
Table 1. Genome-Wide Significant Associationsa
GWAS Phenotype
Single-Nucleotide
Polymorphism Chromosome Base Position A1 OR (95% CI) P Value Position Nearest Gene
Any PE rs10994278 10 62009219 T 1.16 (1.10-1.23) 3.06 × 10−8 Intronic ANK3
Any PE rs549656827 5 35349428 G 0.61 (0.50-0.73) 3.30 × 10−8 Intergenic PRLR
Distressing PE rs75459873 1 24256312 G 0.66 (0.56-0.78) 3.78 × 10−8 Intronic CNR2
Distressing PE rs3849810 8 53009606 A 1.22 (1.13-1.31) 4.55 × 10−8 Intergenic ST18
Abbreviations: A1, risk allele; GWAS, genome-wide association study; OR, odds ratio; PE, psychotic experience.
a Genome-wide significant associations (P < 5 × 10−8) from GWAS analyses.
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schizophrenia. Genetic correlation analysis identified signifi-
cant genetic correlations between psychotic experiences and
major depressive disorder (rg = 0.46), autismspectrumdisor-
der (rg = 0.39),ADHD(rg = 0.24), andschizophrenia (rg = 0.21).
Polygenic risk score analyses identified associations between
psychotic experiences and genetic liability for schizophrenia,
major depressive disorder, bipolar disorder, ADHD, and au-
tism spectrum disorder, andwe found particular enrichment
of these PRS scores in distressing psychotic experiences and
for delusionsof persecution.However, given thepossibility of
sampleoverlapbetween theUKBiobankand the training sets,
the PRS findings should be treated with caution. Themecha-
nisms underlying the high genetic correlation between de-
pression andpsychotic experiences cannot bediscerned from
our analysis, but one possibility is that the psychotic experi-
enceshavearisen in thecontextofmood-relatedchanges, con-
sistent with the strong associations between psychotic expe-
riences and depressive symptoms observed in population-
basedstudies.43Nonetheless,when individualswitha lifetime
history of depression were excluded from PRS analyses, the
association remained, indicating that the findings are not
wholly attributable to depression.
We found an increased burden of CNVs previously asso-
ciated with schizophrenia and neurodevelopmental disor-
ders more widely in individuals with any psychotic symp-
toms and distressing psychotic symptoms, although the
association was stronger for those with distressing psychotic
experiences. All schizophrenia-associated CNVs are also as-
sociatedwithneurodevelopmental disorders such as intellec-
tual disability and autism spectrum disorder; in fact, pen-
Figure 2. Genetic Correlation Analysis
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etrance is higher in individuals with these disorders.39
Furthermore, CNVs in the UK Biobank have been associated
witha rangeofoutcomes, includingcognitiveperformance38,44
and depression,45 adding strength to our findings of a lack of
specificity for genetic risk of psychotic experiences.
Several studies have demonstrated that psychopatho-
logic conditions in the population are best described by a bi-
factormodelwithacommonlatent traitaswellasspecific traits,
and that psychotic experiences index themore severe end of
the common or shared trait.46,47 Our findings of nonspecific-
ity of genetic risk for psychotic experienceswith risk for other
disorders are consistentwith those of previous studies.7,8,11,12
Nonetheless,despite lackingspecificity,our results suggest that
incorporatingquestions aboutdistress to self-reportedassess-
ments of psychotic experiencesmay allow amore valid iden-
tification of experiences that index liability of schizophrenia
andmajor mental health disorders.
In the largest GWAS of psychotic experiences to date, we
identified 4 genome-wide significant loci. However, consis-
tentwithother studies,7,11 theheritability estimate (1.71%)was
low and, given that the variance explained in our PRS analy-
sis was also low, the findings suggest that understanding the
genetics of psychotic experiences is unlikely to have an im-
portant effect on understanding the genetics of schizophre-
nia specifically.
The primary GWAS findings are related to intronic vari-
ants in ANK3 and CNR2. The GWAS of any psychotic experi-
ence identified2 significant loci, themost significant ofwhich
was indexed by rs10994278, an intronic variant toANK3 (OR,
1.16; 95% CI, 1.10-1.23; P = 3.06 × 10−8). The ANK3 gene en-
codes ankyrin-G, aprotein thathasbeenshownto regulate the
assemblyofvoltage-gatedsodiumchannels and is essential for
normal synaptic function.48ANK3 is oneof strongest andmost
replicated genes for bipolar disorder,32 and variants within
ANK3 have also been associated in the Psychiatric Genomics
Consortiumcross-disorderGWAS,49and ina rarevariantanaly-
sis of autism spectrum disorder.50
TheGWASof distressing psychotic experiences also iden-
tified 2 significant loci, the most significant of which was in-
dexed by rs75459873, an intronic variant to CNR2 (OR, 0.66;
95% CI, 0.56-0.78; P = 3.78 × 10−8). CNR2 encodes for CB2, 1
of 2 well-characterized cannabinoid receptors (CB1 being the
other). Several lines of evidence have implicated the endo-
cannabinoid system in psychiatric disorders, including
schizophrenia51,52 and depression.53 The main psychoactive
agent of cannabis, Δ9-tetrahydrocannabinol, can cause acute
psychotic symptoms and cognitive impairment.54 Given that
cannabis use is strongly associated with psychotic experi-
ences, we tested, but found no evidence for, a mediating or
moderating effect of cannabis use on the association of
rs75459873 and distressing psychotic experiences. However,
while no evidencewas found in this study, amediating effect
of cannabis use cannot be ruled out given the relatively low
power of such analyses and the potential measurement error
Figure 3. Polygenic Risk Score (PRS) Analysis
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Spectrum
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Multiple occurrences of a psychotic experience
Distressing psychotic experience The x-axis refers to the PRS tested
(schizophrenia, bipolar disorder,
major depressive disorder, attention
deficit/hyperactivity disorder
[ADHD], autism spectrum disorder,
neuroticism, and intelligence), and
the y-axis represents the odds ratio
(OR). Points display the OR and 95%
CIs (error bars) for each PRS (P < .05
single-nucleotide polymorphism
[SNP] inclusion threshold) regressed
against each psychotic experience
phenotype. Plots displaying multiple
P value SNP inclusion thresholds are
shown in eFigures 8 and 9 in the
Supplement.
Table 2. Association of Psychotic Experience PhenotypesWith CNVsa
Phenotype
Rate, No./Total No. (%)
OR (95% CI) P ValueCase Control
Schizophrenia CNVs
Any PE 59/5829 (1.0) 572/115807 (0.5) 1.54 (1.18-2.01) 1.60 × 10−3
Distressing PE 28/2046 (1.4) 572/115807 (0.5) 2.04 (1.39-2.98) 2.49 × 10−4
Multiple occurrence of PE 28/3177 (0.9) 572/115807 (0.5) 1.34 (0.91-1.94) .14
Neurodevelopmental disorder CNVs
Any PE 83/5829 (1.4) 1058/115807 (0.9) 1.54 (1.23-1.92) 1.89 × 10−4
Distressing PE 34/2046 (1.7) 1058/115807 (0.9) 1.75 (1.24-2.48) 1.41 × 10−3
Multiple occurrence of PEs 38/3177 (1.2) 1058/115807 (0.9) 1.30 (0.92-1.78) .14
Abbreviations: CNV, copy number
variant; OR, odds ratio; PE, psychotic
experience.
a All schizophrenia-associated CNVs
are also included in
neurodevelopmental disorders.
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in cannabis use assessed via lifetime self-report. Indepen-
dent replication of genetic loci identified in this studywill be
required to further understand their role in subclinical psy-
chotic experiences.
Strengths and Limitations
Strengths of this study include the large sample size (approxi-
mately 10 times that of previous studies), the use of an adult
cohort, and the use of multiple psychotic experience pheno-
types, which increase confidence in our findings. This study
also has some limitations. Although we used all available in-
formation to identify and remove individuals with a psy-
choticdisorder, it remainspossible that some individualswere
not identified and remained in the analysis. A further limita-
tion of this study relates to the retrospectivemeasurement of
lifetime psychotic experiences by self-report from an online
questionnaire, as this increases the likelihood of measure-
ment error. A further limitation is the evidence of a “healthy
volunteer” selection bias for the participants recruited to the
UK Biobank and the sample cannot be therefore considered
representative of the general population.55Wealso found that
the participants who completed the MHQ had significantly
higher intelligence and lower schizophrenia, depression, and
neuroticismPRScomparedwithUKBiobankparticipantswho
didnot complete theMHQ (eTable 6 in the Supplement). Last,
we were not able to entirely deduplicate the UK Biobank in-
dividuals fromall theexternaldata setsused for thePRSanaly-
sis; thus, these findings should be treated with caution.
Conclusions
In the largest GWAS of psychotic experiences from the popu-
lation-basedUKBiobanksample,wefoundsupport forashared
genetic liabilitybetweenpsychoticexperiencesandseveralpsy-
chiatric disorders including schizophrenia, major depressive
disorder, bipolar disorder, and neurodevelopmental disor-
ders, indicating that psychotic experiences are not specifi-
cally associatedwith schizophrenia, but ratherwith a general
risk for mental health disorders.
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